Luxiao Li
Overview
Explore the profile of Luxiao Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Y, Tan J, Li L, Liu S, Li X, Shan H, et al.
J Mol Cell Cardiol
. 2025 Mar;
202:1-12.
PMID: 40037428
Metabolic remodeling involving alterations in the substrate utilization is a key feature of cardiac hypertrophy. However, the molecular mechanisms underlying regulation of tricarboxylic acid cycle intermediates by mitochondrial membrane proteins...
2.
Liang N, Yuan X, Zhang L, Shen X, Zhong S, Li L, et al.
Life Metab
. 2025 Jan;
3(5):loae018.
PMID: 39872146
Dyslipidemia affects approximately half of all people with gout, and prior Mendelian randomization analysis suggested a causal role for elevated triglycerides in hyperuricemia (HU), but the underlying mechanisms remain elusive....
3.
Wang Y, Hu M, Cao J, Wang F, Han J, Wu T, et al.
Cell
. 2024 Nov;
188(2):412-429.e27.
PMID: 39591965
Metastatic dissemination to distant organs demands that cancer cells possess high morphological and metabolic adaptability. However, contributions of the cellular lipidome to metastasis remain elusive. Here, we uncover a correlation...
4.
Li L, Zhong S, Li R, Liang N, Zhang L, Xia S, et al.
JCI Insight
. 2022 Apr;
7(7).
PMID: 35393951
HDL cholesterol (HDL-C) predicts risk of cardiovascular disease (CVD), but the factors regulating HDL are incompletely understood. Emerging data link CVD risk to decreased HDL-C in 8% of the world...
5.
Zhong S, Li L, Liang N, Zhang L, Xu X, Chen S, et al.
Redox Biol
. 2021 Mar;
41:101919.
PMID: 33740503
HMG-CoA reductase (HMGCR) is the rate-limiting enzyme in cholesterol biosynthesis and the target for cholesterol-lowering therapy. Acetaldehyde dehydrogenase 2 (ALDH2) is primarily responsible for detoxifying ethanol-derived acetaldehyde and endogenous lipid...
6.
Chen X, Li X, Xu X, Li L, Liang N, Zhang L, et al.
Free Radic Res
. 2021 Jan;
55(4):405-415.
PMID: 33455488
Cardiovascular disease (CVD), including heart attack, stroke, heart failure, arrhythmia, and other congenital heart diseases remain the leading cause of morbidity and mortality worldwide. The leading cause of deaths in...
7.
Li L, Zhong S, Shen X, Li Q, Xu W, Tao Y, et al.
Free Radic Biol Med
. 2019 Jun;
144:16-34.
PMID: 31202785
Polyunsaturated fatty acids (PUFAs) in the cellular membrane can be oxidized by various enzymes or reactive oxygen species (ROS) to form many oxidized lipids. These metabolites are highly bioactive, participating...
8.
Zhong S, Li L, Shen X, Li Q, Xu W, Wang X, et al.
Free Radic Biol Med
. 2019 Apr;
144:266-278.
PMID: 30946962
Cardiovascular diseases (CVD), including ischemic heart diseases and cerebrovascular diseases, are the leading causes of morbidity and mortality worldwide. Atherosclerosis is the major underlying factor for most CVD. It is...
9.
Guo S, Lu J, Zhuo Y, Xiao M, Xue X, Zhong S, et al.
Redox Biol
. 2018 Dec;
21:101069.
PMID: 30576926
Dysregulation of cholesterol metabolism represents one of the major risk factors for atherosclerotic cardiovascular disease (CVD). Oxidized cholesterol esters (oxCE) in low-density lipoprotein (LDL) have been implicated in CVD but...
10.
Zhong S, Li L, Zhang Y, Zhang L, Lu J, Guo S, et al.
J Clin Invest
. 2018 Oct;
129(1):252-267.
PMID: 30375985
Acetaldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme detoxifying acetaldehyde and endogenous lipid aldehydes; previous studies suggest a protective role of ALDH2 against cardiovascular disease (CVD). Around 40% of East...